tbuckley/cabot-search huggingface dataset:
Compulsory fluoridation.
Authors: R N Palmer
Journal: BMJ (1977)

less than 0 1 0', of the organisms originally present on the test surface in the case of skin.2Although a moist mucosal surface should transfer a higher proportion of organisms to the sponge, the subsequent liberation of these organisms is necessarily inefficient in any contact-transfer procedure.If its serious quantitative limitations are borne in mind this procedure should prove a very convenient aid in ecological studies of accessible mucosal surfaces.Certainly this important area of investigation at present lags far behind the flourishing field of skin ecology.
In brief
Journal: BMJ (2008)

The government and the drug industry this week reached an outline agreement on a new contract for drug prices in the United Kingdom over the next five years.It is expected that the deal will cut the annual £9bn (€11bn; $18bn) drug bill in the UK's health services by 5% by 2009.The announcement follows a year of intense and tough negotiations after the Department of Health said it was unilaterally cancelling the current pharmaceutical price regulation scheme (PPRS) halfway through its planned duration (BMJ 2007;335:273).The PPRS, which normally runs for five years, allows companies to set drug prices freely but caps their overall profits.The current scheme began in 2005, with a 7% price cut, and was supposed to end in 2010.Under pressure to cut costs at a time when the growth in the NHS budget is slowing, the government sought a fresh reduction of 10%, arguing that drug prices in Britain were among the highest in Europe.Partly aided by changing exchange rates, the industry claimed instead that British prices were nearer to the European average.It also expressed concerns that the government risked undermining the UK's historical attractiveness for research and development investment by creating instability through reneging on the PPRS deal.The new contract entails a price freeze until the end of this year and then a minimum price cut of 2% in patented drugs at the start of 2009.There will also be bigger reductions in the price of branded drugs no longer on patent, providing an overall reduction of 5%.Further price cuts are possible in future years if the drug bill increases by more than 6.7% annually.In line with recommendations last year from the Office of Fair Trading (BMJ 2007;334:383), the government plans to ensure that prices paid for new drugs more closely reflect the value that they offer.Andrew Jack is the pharmaceuticals correspondent for the Financial Times. Government and industry reach pricing deal to cut drugs bill
Department of Public Health.
Authors: Warren E. Anderson
Journal: JAMA (1898)

Pensacola, Fla., Dec. 15, 1897. Hon. Frank S. Gardner, Secretary Board of Trade and Transportation, New York City. <h3>Dear Sir:</h3> —Please accept many thanks for your valued favor of the 8th instant, with enclosure, dated Washington, Dec. 7, 1897. I had hoped that the calm, dispassionate reason of man would prevail in the discussion so auspiciously begun by us during the past summer, and which gave promise of rich reward so far as the advancement of the health interests of our country was concerned. The sudden and violent interjection, however, into this hitherto friendly contest, of the unwarranted, wanton, unjust and unmanly personal attack upon me by an<i>attaché</i>of the United States Marine-Hospital Bureau at Washington, in a recent letter to you, would seem to have disturbed, temporarily, at least, that serenity and peace of mind so necessary to the performance of a task undertaken in behalf of the
CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.
Authors: Martin Reck, Pablo Gonzalez-Mella, Myung-Ju Ahn, Hassan H. Ghazal, Claus-Peter Schneider, Jacek Jassem, Haolan Lu, Diane Opatt McDowell, Pieter E. Postmus
Journal: Journal of Clinical Oncology (2013)

TPS8117 Background: Improved outcomes for squamous, advanced NSCLC—beyond standard platinum doublets—have not been demonstrated. Data suggestive of response to immune therapies in squamous NSCLC support investigation in this subtype. Ipi, a fully human monoclonal antibody which binds CTLA-4, augments antitumor immune responses. Ipi improved overall survival (OS) in advanced melanoma, with side effects managed using product-specific treatment guidelines. A randomized phase II study of phased Ipi/PC (Ipi started after 2 cycles of PC) in pts with stage IV NSCLC showed significant improvement in progression-free survival (PFS), as measured by mWHO or immune-related response criteria (irRC), with a trend toward prolonged OS, over chemotherapy alone; irRC were derived from WHO criteria to better capture response patterns observed with Ipi. Improvement in PFS and OS appeared greater in tumors of squamous histology. Ipi did not exacerbate PC toxicity, and immune-related adverse events were managed using protocol-specific guidelines. This global (~253 sites among 34 countries) phase III trial (ClinicalTrials.gov identifier NCT01285609) is investigating whether phased Ipi/PC will prolong OS in first-line pts with squamous NSCLC. Methods: Stage IV/recurrent squamous NSCLC with ECOG 0-1 will be included; pts with CNS metastases or history of autoimmune disease will be excluded. Pts are randomized to 2 cycles of PC (175 mg/m 2 and AUC=6, respectively; IV), followed by 4 cycles of study drug (Ipi in Arm A, placebo in Arm B; IV) with 4 additional cycles of PC (total 6 cycles). Pts without progressive disease (PD) after induction receive maintenance therapy with blinded study drug Q12W until PD per mWHO. The study will enroll an estimated 920 pts, randomized 1:1 between arms. The primary endpoint is OS; secondary endpoints include OS among pts who receive blinded therapy, PFS, and best overall response rate. Safety is an exploratory objective of the trial. Clinical trial information: NCT01285609.
Do housemen take an adequate drinking history?
Journal: BMJ (1980)

Changes in mean values of thyroid function tests in patients receiving diclofenac and control group Time after start of study Thyroid test Group Normal range 0 1 month 2 months Triiodothyronine uptake % Diclofenac 108 105 107 Control i11 104 112 Tetraiodothyronine (radioimmunoassay) Diclofenac
From the Alcohol, Drug Abuse, and Mental Health Administration
Authors: Donald Ian Macdonald
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Colonic Pseudoobstruction Syndrome After Jejunoileal Bypass
Authors: Charles E. Wills
Journal: JAMA (1978)

<h3>To the Editor.—</h3> In the QUESTIONS AND ANSWERS section (238:2646, 1977), treatment of colonic pseudoobstruction syndrome after jejunoileal bypass was discussed, and the follow-up demonstrated a successful end. I think that this was a good report, but one important method of management was omitted: the intestinal bypass could be taken down and a gastric bypass performed. The importance of this is realized even more when consideration is given to the fact that this is also applicable to many other undesirable side effects of the jejunoileostomy including diarrhea, electrolyte imbalance, proctitis, renal calculi, liver damage, arthritis, arthralgias, and febrile attacks.<sup>1</sup> From 1963 to 1978 my series of jejunoileostomy has been 765 cases. Since Alden<sup>2</sup>reported optimistic results with gastric bypass, I have taken down jejunoileostomies in seven cases and carried out gastric bypasses with relief of postjejunoileostomy symptoms.
Computer-assisted learning and evaluation in medicine
Authors: T. E. Piemme
Journal: JAMA (1988)

The use of the computer in medical education has been in evolutionary development since the early 1960s; its adoption, however, has been less widespread than the promise of the medium should warrant. Computer-assisted instruction enhances learning, allowing the student the discretion of content, time, place, and pace of instruction. Information conveyed can take several forms, some better suited to undergraduate medical education, others more applicable to graduate and continuing education. The use of the computer in certification and licensure could, within a decade, transform the way competence is assessed. Its greatest promise, however, may lie in providing pertinent information at the time when, and in the place where, patient care takes place. New developments in data storage and retrieval forecast applications that could not have been imagined even a year or two ago. (<i>JAMA</i>1988;260:367-372)
Child Molestation and Pedophilia
Authors: John P. Kemph
Journal: JAMA (1989)

<h3>To the Editor.—</h3> We congratulate the editors of<i>JAMA</i>on the publication of the fascinating and scholarly review by Dr Fuller1<sup>1</sup>entitled "Child Molestation and Pedophilia: An Overview for the Physician." Though otherwise comprehensive, the review omitted emphasis of one of the most prevalent and traumatic categories of child sexual abuse, ie, incest (intrafamilial child sexual abuse). Dr Fuller mentions incestuous abuse only twice in his review. Our concern is that such omission might serve to perpetuate what some have labeled one of this century's greatest tragedies: the failure of society (and medicine) to acknowledge the presence and devastating impact of the scourge of incest on our children. The brief reference to incest might be taken by the reader to imply that incest is not significant enough to warrant discussion, even in a general review. Such cannot be the case when 10% to 50% of all child sexual abuse is
"HUMANITY'S DEBT TO MEDICAL SCIENCE"
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Allergy and Applied Immunology. A Handbook for Physician and Patient, on Asthma, Hay Fever, Urticaria, Eczema, Migraine and Kindred Manifestation of Allergy . By Warren T. Vaughan, M.D. C. V. Mosby Co., St. Louis, Mo., 1931. 352 Pages. Price $4.50.
Journal: New England Journal of Medicine (1932)
Reply
Authors: Alessandro Soria, Giuseppe Lapadula, Massimiliano Fabbiani, Andrea Gori
Journal: Hepatology (2017)

Potential conflict of interest: Dr. Soria consults for AbbVie. Dr. Fabbiani advises, is on the speakers' bureau of, and received grants from Bristol‐Myers Squibb and Gilead. He is on the speakers' bureau of and received grants from MSD, ViiV, and Janssen‐Cilag. Dr. Gori advises and received grants from Bristol‐Myers Squibb and Gilead. He received grants from ViiV and MSD. Reply: We thank Dr. Ji and colleagues for their interest in our observation regarding a reduced sustained virological response of hepatitis C treatment with direct‐acting antivirals (DAAs) in patients with active hepatocellular carcinoma (HCC).1 Since then, a growing body of evidence has supported our original findings as in five independent cohorts the association goes in the same direction, accruing consistency of different observations in different contexts.1 The meta‐analysis of Asian patients by Ji et al. enforces the association by showing a lower sustained virological response in HCC patients treated with ledipasvir/sofosbuvir but no difference when treated with asunaprevir/daclatasvir. The authors speculate on the possible influence of a DAA regimen, trying to compare subgroups in their analysis and recalling that of the US cohort of veteran patients.3 However, they refer to patients with prior history of HCC. On the basis of available data, we do not think that the mechanism of a reduced efficacy of DAA in patients with active HCC should be looked for in different associations of specific DAA drugs: subgroups of these studies are small, uncontrolled, and casual; moreover, the association of daclatasvir/asunaprevir is not feasible outside certain Asian countries as asunaprevir will never be licensed in Europe and the United States. Comparison of regimens which include suboptimal and outdated therapies without head‐to‐head randomized clinical trials is useless. Rather, practical implications deriving from this strong association are on (1) timing of DAA treatment in patients on the list for liver transplantation, (2) timing of DAA treatment with respect to HCC treatment (surgery, radiofrequency, or chemoembolization), and (3) DAA treatment duration. All of these aspects should be tested in larger and well‐controlled trials, while in the meantime further efforts to untangle biological mechanisms underpinning this phenomenon should be pursued. So far, the available data demonstrate that sustained virological response is lower in patients with active HCC than in those with a history of HCC who were treated1 or transplanted2 for their tumor. This finding was consistent across different small1 and larger3 cohorts, suggesting a role of the peculiar biology of HCC cells in determining the lower success of DAAs.
'Bubble Boy'
Authors: Drummond Rennie
Journal: JAMA (1985)

David, the "Bubble Boy" was born on Sept 21, 1971. Because he had an even chance of developing severe combined immunodeficiency disease (SCID), the disease that had killed his brother, he was delivered by cesarean section into a sealed chamber. Frequent newspaper reports during the succeeding years described a growing David and ever-larger sterile plastic chambers—the "bubbles." A combination of extraordinary and imaginative technology, medical care by the team at Texas Children's Hospital and Baylor College of Medicine, as well as the devotion of his own family allowed David to remain free of contact with organisms and, so, free of disease. He celebrated his 12th birthday "with a family party, a chocolate cake and a Roman Catholic communion using a sterilized wafer" (<i>New York Times</i>, Sept 22, 1983, p A-14). He was the oldest "untreated" survivor of SCID. Despite transplantation on Oct 21, 1983, of bone marrow previously treated using
Studies of Male Survivors of Myocardial Infarction Due to "Essential" Atherosclerosis: II. Lipids and Lipoproteins
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maxillary antral cancers
Authors: L. G. Larsson
Journal: JAMA (1972)

Cancer in the paranasal sinuses and nasal cavities in a relatively rare tumor disease, with an annual incidence of about one case per 100,000 inhabitants in Europe and the United States.<sup>1</sup>The majority of these tumors start in the mucous membrane of the maxillary antrum or the ethmoid labyrinth. A few cases originate from the nasal cavities, while primary cancers in the sphenoid and frontal sinuses are extremely rare. The age-specific incidence of the disease continuously increases with age; it is predominately a disease of the middle aged and aging. The only known etiologic factor of some importance in antral carcinoma is chronic sinusitis. Long-standing sinusitis causes a squamous cell metaplasia of the respiratory epithelium, which probably is the origin of most antral cancers. Some patients have a long history with signs of chronic sinusitis, prior to the signs of progressive tumor. Squamous cell carcinoma is the most frequent
Fourteen Strains of Cells Certified
Journal: JNCI Journal of the National Cancer Institute (1963)

Journal Article Fourteen Strains of Cells Certified Get access JNCI: Journal of the National Cancer Institute, Volume 30, Issue 2, February 1963, Page 399, https://doi.org/10.1093/jnci/30.2.399-a Published: 01 February 1963
A Family Doctor's Notebook
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An epidemiological study of lung cancer: history and histological types in a general population in northern Finland
Authors: R. Makitaro, P. Paakko, E. Huhti, R Bloigu, V.l. Kinnula
Journal: European Respiratory Journal (1999)

A prospective epidemiological study was conducted to assess the incidence, diagnosis, histology and surgical treatment of lung cancer in northern Finland. The results were compared with those obtained in a similar survey 20 yrs earlier. Most of the patients with a suspected lung tumour were interviewed (72%) and the information was combined with that obtained from the national cancer registry. All pathological specimens were re-evaluated by a pathologist. A total of 602 new lung cancer cases (85% male, 15% female) were diagnosed during the years 1990-1992, the annual incidence per 100,000 being 63 for males and 9.5 for females. The number not reported to the Finnish Cancer Registry was low (&lt;1%). Lung cancer was confirmed histologically in 381 cases (63%) and in addition cytologically in 135 cases (23%). Squamous cell carcinoma was the most common histological type (40%), the proportion of adenocarcinoma being 26%, small cell carcinoma 24% and large cell carcinoma 4%. The incidence of lung cancer had decreased significantly among males (from 87 to 63 per 100,000) compared with 20 yrs earlier but had increased among females (from 4.1 to 9.5), chiefly on account of adenocarcinoma. The findings of this prospective study show an increase in the incidence of lung adenocarcinoma among females, a histological type which is less closely related to smoking than the other cancers. This suggests that other risk factors may play an increasing role in the aetiology of lung cancer.
ALCOHOL AND INSANITY.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Funerals.
Authors: A I Neugut
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.10.2887 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8874354 Funerals. A I NeugutxA I NeugutSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.10.2887 PDF "Funerals.." Journal of Clinical Oncology, 14(10), pp. 2887–2888© 1996 by American Society of Clinical Oncology